Overview

A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors

Status:
Recruiting
Trial end date:
2022-12-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether romiplostim can help prevent low platelet counts caused by N8 or EFT chemotherapy, reduce the number of platelet transfusions required during chemotherapy, and prevent treatment delays due to low platelet counts.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center